دورية أكاديمية
Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
| العنوان: | Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review |
|---|---|
| المؤلفون: | Mar Sempere-Bigorra, Iván Julián-Rochina, Omar Cauli |
| المصدر: | Current Oncology, Vol 28, Iss 4, Pp 3124-3138 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | toxicity, side effects, cold sensitivity, autonomic dysfunction, regimens, cytostatic drugs, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. The deleterious effects of chemotherapy on diabetic patients seem to last longer, since peripheral neuropathy persisted in a higher proportion of diabetic patients than non-diabetic patients for up to two years after treatment. Future studies investigating the risk of developing peripheral neuropathy in cancer patients with comorbid diabetes need to consider the duration of diabetes, cancer-induced neuropathic effects per se (prior chemotherapy administration), and the effects of previous cancer management strategies such as radiotherapy and surgery. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1718-7729 1198-0052 |
| العلاقة: | https://www.mdpi.com/1718-7729/28/4/273Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test |
| DOI: | 10.3390/curroncol28040273 |
| الوصول الحر: | https://doaj.org/article/acbe74d7ee96422e8a9f3562a168ec4dTest |
| رقم الانضمام: | edsdoj.be74d7ee96422e8a9f3562a168ec4d |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17187729 11980052 |
|---|---|
| DOI: | 10.3390/curroncol28040273 |